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Metabolic acidosis is common in patients with chronic
kidney disease, which is known to affect bone metabolism.
We examined the effect of metabolic acidosis on the
development of vascular and other soft-tissue calcifications
in uremic rats treated with calcitriol. Extraskeletal calcification
was measured in vivo, in control rats and rats with a remnant
kidney model of uremia with or without ammonium
chloride-induced acidosis. Soft-tissue calcification was
assessed histologically, by measurement of the expression
of the sodium-dependent phosphate cotransporter
Pit-1 and by quantification of tissue calcium and
phosphorus. Calcitriol administration to uremic rats
resulted in significant deposition of material positive
for von Kossa stain in the aorta, stomach, and kidney,
elevated aortic calcium and phosphorus, increased aortic
Pit-1 expression, and high mortality. Calcitriol-treated uremic
rats with acidosis did not develop aortic or soft-tissue
calcification, did not increase aortic Pit-1 expression, and had
significantly lower mortality. Additionally, an acidotic
environment prevented calcification of vascular smooth
muscle cells in vitro. Our study shows that metabolic
acidosis inhibits extraskeletal calcification.
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Extraosseous calcifications, particularly vascular calcifications
(VCs), are frequently observed in patients with chronic
kidney disease (CKD) and represent an important risk
factor for cardiovascular death.1,2 In addition to ischemic
heart disease, VCs are also related to uremic peripheral
vasculopathy.3 CKD patients are affected by both intimal
calcification (atherosclerosis) and medial calcification (arterio-
sclerosis), but the latter seems to be more prevalent.4
Medial calcifications are associated to treatment with
calcitriol and other vitamin D derivatives, which are used for
management of secondary hyperparathyroidism (HPT).5–8
The effects of calcitriol on VC are both indirect (mediated
through an increase in blood calcium (Ca) and phosphorus
(P)) and direct. Vascular smooth muscle cells (VSMCs)
express vitamin D receptors and thus are responsive to
calcitriol.9–11
Metabolic acidosis is also a common complication in
patients with CKD, which is known to have deleterious effects
on bone metabolism.12 Acidosis has been shown to promote
physicochemical bone dissolution, to activate osteoclast-
mediated calcium release from bone, and to inhibit bone
formation by osteoblasts.13,14 The effect of acidosis on the
development of VC is unclear. Medial calcification involves
transdifferentiation of VSMCs to osteoblast-like cells.15
Therefore, it can be hypothesized that the effects of acidosis
on bone could also be extrapolated to VC. This contention is
supported by recent in vitro data, which suggest that a
decrease in pH prevents calcium deposition in cultured rat
aortas.16 However, in vivo, acidosis is also known to induce
vascular wall damage,17 which could initiate or aggravate the
calcification process.
The current study was conducted to investigate the in vivo
effect of metabolic acidosis on the development of vascular
and other soft-tissue calcifications in a rodent model of
uremia.
RESULTS
Plasma biochemistry is shown in Table 1. Plasma creatinine
was significantly (Po0.001) increased in all 5/6 Nx groups.
Nephrectomy alone did not influence the acid–base balance
of the rats. However, administration of NH4Cl resulted in
decreased pH and bicarbonate in all groups when compared
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with their nonacidotic control (in 5/6 Nx rats, pH decreased
from 7.44±0.01 to 7.20±0.03 and bicarbonate, from
29.2±1.1 to 15.8±1.4 mmol l1). Calcitriol-treated rats
showed more marked (Po0.001 vs 5/6 Nxþ acidosis)
decrease in pH and bicarbonate after drinking 0.5%
NH4Cl (7.06±0.07 and 11.0±1.2 mmol l
1, respectively).
Ionized calcium levels were not different in sham
(1.21±0.01 mmol l1) and 5/6 Nx (1.19±0.01 mmol l1)
rats. Treatment with calcitriol increased Ca2þ in 5/6 Nx rats
(1.27±0.02 mmol l1, P¼ 0.01 vs 5/6 Nx), and hypercalce-
mia was further aggravated by acidosis (1.48±0.03 mmol l1,
Po0.001 vs all other groups). Calcitriol-treated rats also
showed higher P levels than the other experimental groups.
Plasma parathyroid hormone (PTH) concentrations were
higher in 5/6 Nx than in sham rats (115.5±11.4 vs
28.5±5.6 pg ml1, Po0.001). Acidosis did not influence
PTH in the sham group but resulted in a slight decrease in
PTH in the 5/6 Nx rats to 80.1±23.5 pg ml1 (Po0.05).
Treatment with calcitriol significantly decreased PTH levels
(37.0±13.9 pg ml1, Po0.001 vs 5/6 Nx), and the decrease
was more marked in the acidotic rats treated with calcitriol
(4.7±1.2 pg ml1). Uremic rats treated with calcitriol that
received 0.3% NH4Cl showed pH (7.31±0.02) and bicarbo-
nate (15.1±0.8 mmol l1) values that were not different from
the 5/6 Nxþ acidosis group. These rats were hypercalcemic
(1.35±0.02 mmol l1), hyperphosphatemic (10.1±0.6 mg
per 100 ml), and had decreased PTH (10.1±1.8 pg ml1).
Aortic Ca content was low in sham-operated rats
(2.1±0.2 mg per g of tissue). Neither acidosis nor nephrec-
tomy modified aortic Ca content. However, treatment with
calcitriol significantly increased aortic Ca content in 5/6 Nx
rats (4.4±0.9 mg per g of tissue, P¼ 0.001 vs 5/6 Nx).
Interestingly, acidotic rats treated with calcitriol did not
increase aortic Ca content: 1.8±0.2 mg per g of tissue
(NH4Cl, 0.5%) and 1.4±0.1 mg per g of tissue (NH4Cl,
0.3%), Po0.001 vs 5/6 Nxþ calcitriol and NS vs all
other groups (Figure 1a). Changes in aortic phosphorus
mirrored those of aortic calcium. A significant increase in
aortic P level was detected in 5/6 Nx rats treated
with calcitriol (2.2±0.7 mg per g of tissue, Po0.05 vs all
the other groups), and again, acidosis prevented the
calcitriol-induced increase in aortic phosphorus:















(mg per 100 ml)
0.56±0.02a,b,c,d 0.55±0.02a,b,c,d 0.93±0.02 0.99±0.06 1.04±0.07 1.14±0.89a 1.14±0.10a
pH 7.42±0.01c,d 7.31±0.01a,b,c 7.44±0.01 7.20±0.03a,b,c,d 7.46±0.02 7.06±0.07a,b 7.31±0.02a,b,c
Bicarbonate
(mmol l1)
28.2±1.8c,d 21.1±0.9a,b,c,d 29.2±1.1 15.8±1.4a,b,c 28.1±0.7 11.0±1.2a,b 15.1±0.8a,b,c
Ca2+ (mmol l1) 1.21±0.01c,d 1.23±0.02c,d 1.19±0.01 1.22±0.01b,c,d 1.27±0.02a 1.48±0.03a,b 1.35±0.02a,b,c
Phosphorus
(mg per 100 ml)
6.3±0.4b,c,d 6.4±0.5b,c,d 6.8±0.4 6.9±0.3b,c,d 9.7±0.7a 8.4±0.2a,b 10.1±0.6a,c
PTH (pg ml1) 28.5±5.6a 16.0±6.1a 115.5±11.4 80.1±23.5a,b,c,d 37.0±13.9a 4.7±1.2a,b 10.1±1.8a
PTH, parathyroid hormone.
Plasma biochemistry in sham-operated rats (Sham) and uremic rats treated with vehicle (5/6 Nx) or calcitriol (5/6 Nx+CTR), with normal pH or receiving NH4Cl in drinking
water at 0.75% (Sham+AC 0.75%), 0.5% (5/6 Nx+AC 0.5% and 5/6 Nx+CTR+AC 0.5%), or 0.3% (5/6 Nx+CTR+AC 0.3%).
aPo0.05 vs 5/6 Nx.
bPo0.05 vs 5/6 Nx+CTR.
cPo0.05 vs 5/6 Nx+CTR+AC 0.5%.












































































Figure 1 | Mineral content ((a) calcium, (b) phosphorus) of the
aorta in sham-operated rats (Sham) and uremic rats treated with
vehicle (5/6 Nx) or with calcitriol 80 ng kg1 i.p. q.o.d. for 14 days
(5/6 NxþCTR). All groups are shown with normal pH and with
acidosis, which was induced by administration of NH4Cl in drinking
water at 0.75% (ShamþAC 0.75%), 0.5% (5/6 NxþAC 0.5% and 5/6
NxþCTRþAC 0.5%), or 0.3% (5/6 NxþCTRþAC 0.3%). aPo0.01 vs
5/6 NxþCTR.
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0.7±0.1 mg per g of tissue (NH4Cl, 0.5%) and 0.9±0.1 mg
per g of tissue (NH4Cl, 0.3%), Po0.01 vs 5/6 Nxþ calcitriol
(Figure 1b).
Aortic tissue sections from nephrectomized rats are shown
in Figure 2. Neither sham operated, 5/6 Nx, nor 5/6
Nxþ acidosis rats showed any mineral deposits in the aorta
(Figure 2a–c). Moderate mineral deposition was detected by
von Kossa staining in the media of the 5/6 Nx rats treated
with calcitriol. Calcium deposits showed a patchy concentric
pattern along the tunica media (Figure 2d). Interestingly, the
5/6 Nx rats that were treated with calcitriol and made
acidotic did not show mineral deposits in their aortas (Figure
2e and f).
The soft-tissue mineral content in the rats that did not
receive calcitriol had low-gastric content of calcium and
phosphorus ranging between 0.1 and 0.2 mg per g of tissue
and 0.4 and 0.5 mg per g of tissue, respectively (Figure 3).
Accordingly, no von Kossa staining was detected in tissue
sections from these groups. Nephrectomized rats treated with
calcitriol showed significant (Po0.05) increases in both
gastric calcium (1.6±0.7 mg per g of tissue) and phosphorus
(1.5±0.6 mg per g of tissue), which were readily observed in
the von Kossa-stained tissue sections (Figure 4). However, the
acidotic rats (0.5% NH4Cl) treated with calcitriol did not
increase the gastric mineral content (Ca¼ 0.2±0.1 mg per
g of tissue, P¼ 0.4±0.1 mg per g of tissue, NS vs 5/6 Nx).
The rats that received 0.3% NH4Cl showed higher gastric Ca
(0.8±0.1 mg per g of tissue) and P (0.7±0.1 mg per g
of tissue) than the rats that drank 0.5% NH4Cl, but this level
of mineralization was still significantly lower (Po0.01) than
their normal pH controls (Figure 3). von Kossa staining was
not detected in the soft tissues of acidotic rats (0.5% NH4Cl)





 Sham  5/6 Nx  5/6 Nx+AC 0.5%
 5/6 Nx+CTR+AC 0.3% 5/6 Nx+CTR+AC 0.5% 5/6 Nx+CTR
Figure 2 | Aortic calcification. von Kossa-stained tissue sections of the aorta in sham-operated rats (Sham, a), in uremic rats with normal pH
(5/6 Nx, b) and with acidosis (5/6 NxþAC 0.5%, c), and in uremic rats treated with calcitriol, 80 ng kg1 i.p. q.o.d. for 14 days with normal
pH (5/6 NxþCTR, d) and with acidosis: 0.5% NH4Cl (5/6 NxþCTRþAC 0.5%, e) and 0.3% NH4Cl (5/6 NxþCTRþAC 0.3%, f).









































































Figure 3 | Mineral content ((a) calcium, (b) phosphorus)
of the stomach in sham-operated rats (Sham) and uremic rats
treated with vehicle (5/6 Nx) or with calcitriol 80 ng kg1 i.p.
q.o.d. for 14 days (5/6 NxþCTR). All groups are shown with normal
pH and with acidosis, which was induced by administration
of NH4Cl in drinking water at 0.75% (ShamþAC 0.75%), 0.5%
(5/6 NxþAC 0.5% and 5/6 NxþCTRþAC 0.5%), or 0.3% (5/6
NxþCTRþAC 0.3%). aPo0.01 vs 5/6 NxþCTR, bPo0.05 vs 5/6
NxþCTRþAC 0.3%.
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No deaths were recorded during the first 15 days of the
study in any experimental group. At 30 days, 4 out of the 10
(4/10) 5/6 Nx rats treated with calcitriol died. By contrast,
only one (1/10) of the 5/6 Nx rats receiving 0.3%
NH4Clþ calcitriol died.
An increase in Pit-1 (mRNA Pit-1 vs mRNA b-actin)
expression was detected in the calcified aortas of calcitriol-
treated rats. Pit-1 was significantly (Po0.05) higher in the
5/6 Nxþ calcitriol group (1.70±0.38) than in the 5/6 Nx
group (1.05±0.23). Expression of Pit-1 in aortic tissue was
lower (Po0.05 vs 5/6 Nxþ calcitriol) in the 5/6 Nxþ acido-
sis (0.87±0.07) and 5/6 Nxþ acidosisþ calcitriol
(0.77±0.08) groups of rats.
Results of the in vitro studies are shown in Figure 5.
Bovine VSMCs cultured at normal pH (7.4) with b-
glycerophosphate (5 mM) showed extensive Alizarin red
staining and high calcium levels (7.6±0.7 mg Ca per mg
protein). By contrast, when these cells were incubated at low
pH (7.2), no staining was detected and the calcium levels
(1.2±0.1 mg Ca per mg protein) were not different from
their control levels without b-glycerophosphate (0.7±0.5 mg
Ca per mg of protein).
DISCUSSION
The study reported here investigated the influence of
metabolic acidosis on the development of calcitriol-induced
extraosseous calcifications in a rat model of uremia. Our
results show that acidosis caused by ingestion of NH4Cl
prevents the development of extraskeletal calcifications in
uremic rats treated with calcitriol, even though the plasma Ca
and P were increased in these rats.
Acidosis is a common complication of uremia that can
contribute to the development of arterial wall inflamma-
tion.17 Acidosis has been reported to increase the production
of IL-6 and the chemokine RANTES from smooth muscle
cells in vitro.18 In vivo, Pickering et al.19 reported a decrease in
TNF plasma levels after correction of acidosis in patients
receiving chronic ambulatory peritoneal dialysis. Since
arterial wall inflammation is a well-known stimulus for VC,
it can be speculated that acidosis could promote VC.
Medial calcifications (arteriosclerosis) are the more
prevalent form of VC in uremic patients.4 In medial
calcifications, there is a transdifferentiation of VSMCs to
osteoblastic cells, which ultimately can lead to osteoid tissue
formation in the arterial wall.15 The effect of acidosis on bone
has been extensively studied, and the available data indicate
that acidosis promotes bone dissolution through a series of
physicochemical and cellular mechanisms.12–14 Thus, it was
hypothesized that acidosis could also act on extraskeletal
calcifications in a manner similar to bone. This contention is
supported by in vitro data demonstrating decreased mineral
deposition in rat aortas cultured at low pH.16 In vivo, acidosis
has also been associated with decreased calcium deposition in
the kidneys of azotemic rats.20 Furthermore, clinical studies
also suggest that acidifying agents may be useful in the
treatment of extraosseous calcifications.21
To determine the influence of acidosis on the development
of extraskeletal calcifications, we have used a model of
calcitriol-induced calcifications in 5/6 Nx rats. This model,
which has been previously reported,22 has the advantage of
resembling the clinical situation in patients with CKD, since
many of these patients are treated with vitamin D derivatives
for the control of secondary hyperparathyroidism. In this
study, calcitriol has been administered at the dose that
is required to normalize PTH levels in 5/6 Nx rats.22

















Figure 4 | von Kossa-stained tissue sections of the kidney
and the stomach of uremic rats (5/6 Nx) treated with calcitriol,
80 ng kg1 i.p. q.o.d. for 14 days with normal pH (5/6 NxþCTR)
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Figure 5 | In vitro studies of calcification using bovine VSMC
incubated at normal (7.4) or low (7.2) pH with or without
b-glycerophosphate (5 mM). (a) Calcium content; (b) Alizarin
red stain.
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changes in pH or bicarbonate, thus representing a good
control group for 5/6 Nx acid-treated rats.
Our results clearly show that acidosis prevents the
development of extraosseous calcifications in uremic rats
treated with calcitriol. Two mechanisms are commonly
implicated on the calcifying effect of calcitriol and other
vitamin D analogs: a direct effect on VSMC, which have
vitamin D receptors;9–11 and an indirect effect mediated
through the elevations of extracellular Ca and P.6 It is
interesting to note that the acidotic rats treated with calcitriol
experienced more severe hypercalcemia than their normal pH
controls (5/6 Nxþ calcitriol). Phosphorus was significantly
reduced in the 5/6 Nxþ calcitriol group that received 0.5%
NH4Cl, and this could also have played a role in preventing
calcifications. Nonetheless, the Ca P product was increased
in both acid-treated groups (0.3 and 0.5% NH4Cl). Also of
interest is the fact that acidosis tended to decrease PTH
concentrations. We have previously demonstrated an acute
direct stimulatory effect of acidosis on PTH secretion23 and
have also shown that this effect is counteracted by acidosis-
induced hypercalcemia.24 Therefore, the decreased PTH levels
detected in acidotic rats are likely to be secondary to the
elevations in plasma calcium. In conclusion, the data of this
study indicate that the preventive effect of acidosis on
calcifications is evident even in the face of high plasma
Ca P product.
Since metabolic acidosis had a significant effect on PTH
and phosphate levels, which are known to affect calcification,
in vitro studies were conducted to isolate the effect of acidosis
from other changes in mineral metabolism. Our results,
which are in agreement with previous in vitro studies,16 show
that acidosis also prevented the development of calcifications
in cultures of bovine VSMC, where PTH was not present and
phosphate levels were controlled. Thus, although in vivo PTH
and phosphate may have some modulatory effect on the
anticalcifying effect of acidosis, the in vitro experiments
demonstrate that acidosis by itself can prevent calcifications.
Two direct mechanisms could potentially be involved in
the protective effect of acidosis on extraskeletal calcifications:
(a) a physicochemical mechanism; and (b) a cellular
mechanism. The physicochemical mechanism is based on
the well-known fact that acidosis decreases Ca and P
deposition by increasing their solubility. It has been reported
that the calcium and phosphate solubility for hydroxyapatite
increases two- and fourfold, respectively, when pH is reduced
from 7.40 to 6.90.25 The cellular mechanisms are more
complex; in the process of medial calcification, calcifying
VSMC, a subpopulation of VSMC, experience phenotypic
changes and are transformed into cells that are very similar if
not the same as osteoblasts.15 This phenotypic transforma-
tion is known to be triggered by vitamin D analogs, such as
calcitriol. Metabolic acidosis has been reported to inhibit the
production of collagen and other matrix components by
mouse osteoblasts.26,27 More recent studies have shown a
downregulation of alkaline phosphatase and an upregulation
of matrix-gla protein by metabolic acidosis in cultured rat
osteoblasts.28 Thus, it is likely that even if calcifying VSMC
are activated by calcitriol to be transdifferentiated into
osteoblasts, at low pH, they may be ineffective in producing
osteogenic proteins.
Phosphate uptake through the sodium-dependent phos-
phate cotransporter (Pit-1) has been reported to be essential
for VSMC calcification.29 Our results show that VC was
associated with increased Pit-1 expression in rat aortic tissue
and that acidosis prevented the upregulation of Pit-1. Thus,
in calcitriol-treated rats, acidosis may in fact limit cellular
phosphate uptake by preventing upregulation of Pit-1.
In a previous study, we have demonstrated that cellular
mechanisms affecting cells of the monocytic–macrophagic
lineage are involved in regression of VCs.30 These cells, which
migrate from the vascular lumen to the calcifying foci and
phagocyte mineral, behave in a manner similar to osteoclasts.
Acidosis has been shown to stimulate osteoclast function.
Thus, an attractive hypothesis on the role of acidosis would
be an increase in the mechanisms of mineral clearance at the
arterial wall. However, the microscopic study did not show
mononuclear phagocyting cells either at the arterial wall or in
other soft tissues.
The group of nephrectomized rats that were treated with
calcitriol and received 0.5% NH4Cl showed more marked
metabolic acidosis than their nontreated controls (5/6
Nxþ acidosis), as demonstrated by the lower pH and
bicarbonate values. This finding was unexpected and could
be due to several factors: (1) calcitriol treatment may
deteriorate renal function (as shown by the increased
creatinine values and renal von Kossa staining) and impair
the renal handling of the added acid; (2) the lower PTH
values in calcitriol-treated rats could impair bone buffering
of the acid load;31 (3) calcitriol-induced hypercalcemia may
cause polyuria/polydipsia and thus increase water (and
NH4Cl) consumption. Water consumption was measured in
the different groups to test the latter hypothesis. Calcitriol-
treated rats (5/6 Nxþ calcitriolþ acidosis) drank
4.0±0.3 ml h1, which is about twice the water consumption
of the 5/6 Nx group (2.3±0.3 ml h1, Po0.001). Thus, an
increase in acid intake, probably secondary to hypercalcemia-
induced polyuria/polydipsia, seems to be the more likely
explanation for the lower pH observed in the calcitriol-
treated rats.
An additional group of nephrectomized rats treated with
calcitriol, in which the NH4Cl concentration in drinking
water was reduced to 0.3%, was also studied to compare rats
with a similar degree of metabolic acidosis. These rats, which
experienced a reduction in pH and bicarbonate similar to the
5/6 Nxþ acidosis group, did not develop aortic calcifications,
and when compared with their normal pH controls, had
significantly reduced calcium deposition in soft tissues. Thus,
a moderate degree of metabolic acidosis seems to be
sufficient to prevent extraskeletal calcifications. Also of
importance is the fact that, in accordance with their reduced
mineral levels, the number of dead rats was lower in the
group that received acid treatment (0.3% NH4Cl).
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In conclusion, we have shown that vascular and soft-tissue
calcifications, induced by calcitriol administration to uremic
rats, can be prevented by metabolic acidosis, even though
acidotic rats have a high plasma Ca P product. Since
acidosis prevents upregulation of vascular Pit-1 expression, a
possible mechanism for its anticalcifying effect may be
reduced cellular uptake of phosphate. Although more
preclinical data are needed and any clinical application of
these results should consider the potential negative effects of
acidosis, the data reported here could contribute to improve




Male Wistar rats weighing 250 g were purchased from the Animal
Breeding Facility of the University of Cordoba (Spain). Rats were
housed with a 12/12-h light/dark cycle and given ad libitum access to
normal diet (calcium: 0.9%, phosphorus: 0.6%). The experimental
protocols were reviewed and approved by the Ethics Committee for
Animal Research of the University of Cordoba (Spain), and all
animals received humane care in compliance with the Principles of
Laboratory Animal Care formulated by the National Society for
Medical Research, and the Guide for the Care and Use of Laboratory
Animals prepared by the National Academy of Science.
5/6 nephrectomy
The rodent model of CKD used in these studies was induced by 5/6
nephrectomy (5/6 Nx), a two-step procedure that reduces the
original functional renal mass by five-sixths (5/6). In the first step,
animals were anesthetized using xylazine (5 mg kg1, i.p.) and
ketamine (80 mg kg1, i.p.), an 8-mm incision was made on the left
mediolateral surface of the abdomen, and the left kidney was
exposed. The two renal poles were tightly ligated and ablated, thus
leaving 1/3 of the original renal mass. After 1 week of recovery, the
animal was reanesthetized, and an 8-mm incision was made on the
right mediolateral surface of the abdomen. The right kidney was
exposed and unencapsulated, the renal pedicle clamped and ligated,
and the kidney was removed. Sham-operated animals underwent the
same procedures without renal manipulation.
Experimental design
The experimental schedule is shown in Figure 6. After the second
surgery, the diet was changed to slightly increased phosphorus
(0.9%) content. The rats were randomly assigned (based on the
normal distribution of baseline body weights) into six experimental
groups: sham operated (n¼ 12), sham operatedþ acidosis (n¼ 13),
5/6 Nx (n¼ 14), 5/6 Nxþ acidosis (n¼ 13), 5/6 Nxþ calcitriol
80 ng kg1 i.p. q 48 h (Calcijex, Abbot, Madrid, Spain) (n¼ 17), and
5/6 Nxþ calcitriol 80 ng kg1 q 48 hþ acidosis (n¼ 12).
To induce metabolic acidosis, NH4Cl was added to the drinking
water to form a 0.75% solution of NH4Cl in sham-operated rats and
a 0.5% solution of NH4Cl in Nx rats.
32 Since rats treated with
calcitriol developed more severe acidosis than the other experi-
mental groups, an additional group of 5/6 Nxþ calcitriol 80 ng kg1
q 48 hþ acidosis rats (n¼ 11), in which the concentration of NH4Cl
in drinking water was adjusted to 0.3%, was also studied.
Treatments were maintained for 14 days. At day 14, rats were
killed by aortic puncture and exsanguination under general
anesthesia (i.p. sodium thiopental). In the calcitriol-treated rats,
euthanasia was performed 24 h after receiving the last dose of
calcitriol.
Twenty additional rats that received the treatment protocol 5/6
Nxþ calcitriol (n¼ 10) and 5/6 Nxþ calcitriolþ acidosis (0.3%
NH4Cl) (n¼ 10) were followed up to 30 days for death-rate
assessment.
Blood and tissue sampling
Blood was obtained under anaerobic conditions from the aorta. The
thoracic aortas were dissected and divided into three parts, which
were used for (a) histology; (b) measurement of tissue calcium
and phosphorus content; and (c) quantification of Pit-1 mRNA.
In addition, the stomach and the remnant kidney were removed
Normal phosphorus diet
(Ca=0.9%, P=0.6%)
0 1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Time (days)
Acidosis: NH4Cl in drinking water
CTR CTR CTR CTR  CTR  CTR CTR
Treatment groups:
Sham-operated
Sham-operated+acidosis (0.75% NH4Cl in drinking water)
5/6 Nx+vehicle
5/6 Nx+acidosis (0.5% NH4Cl in drinking water)
5/6 Nx+80 ng kg–1 calcitriol q 48 h
5/6 Nx+80 ng kg–1 calcitriol q 48 h+acidosis (0.5% NH4Cl in drinking water)







Figure 6 | Experimental design of the in vivo studies.
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to study soft-tissue calcifications. Both histopathological studies
(hematoxylin–eosin and von Kossa stains) and measurement of tissue
calcium and phosphorus content were performed on tissue samples.
Quantification of aortic and gastric mineral content
For quantification of aortic Ca and P contents, the aortas were
demineralized in a 10% formic acid solution. Subsequently, Ca and P
contents were measured in the supernatant as described below.33
Measurements of aortic Ca and P concentrations are reported as per
dry weight. Quantification of organ mineral accumulation was carried
out as previously reported.34 Briefly, the stomach from each animal
was placed into separate 30-ml tubes. Twenty milliliters of 150-mM
HCl was added to each tube. The tubes were mixed end over end for
24 h at room temperature, and Ca and P concentrations were
measured in the acid extract by spectrophotometry as described below.
Biochemical measurements
Ionized calcium, PaCO2, and pH were measured using a selective
electrode (model 634; Ciba Corning, Essex, England). Bicarbonate
was calculated from pH and PaCO2 values using the Henderson–-
Hasselbach equation. Intact PTH was quantified according to
the vendor’s instructions using the rat-specific IRMA assay
(Scantibodies Laboratories Inc., Santee, CA, USA). Creatinine,
phosphate, and total calcium were measured by spectrophotometry
(BioSystems SA, Barcelona, Spain).
Pit-1 mRNA measurement (RNA isolation and real-time
(RT)-PCR)
Fresh aortic tissue was dry-frozen in liquid nitrogen and stored at
801C until RNA isolation. For RNA isolation, 1 ml of phenol–-
guanidine isothiocyanate solution (Tri-Reagent; Sigma, St Louis,
MO, USA) was added to the aortic tissue. Tissue samples were
ultrasonicated for 5 min at 41C to allow for complete cell rupture.
Thereafter, total RNA was extracted following a modification of the
Chomczynski and Sacchi protocol35 and dissolved in nuclease-free
water (Promega, Madison, WI, USA). Total RNA was quantified by
spectrophotometry. Pit-1 vs b-actin was amplified with an RT-PCR
kit (QuantiTect SYBR green; Qiagen, Hilden, Germany) using
specific primers and 100 ng of total RNA per sample. The following
primers were used: Pit-1 (sense) CCGTCAGCAACCAGATCAACTC,
(antisense) CCCATGCAGTCTCCCACCTTG; and b-actin (sense)
TGTAACCAACTGGGACGATATGGA, (antisense) ACAATGCCAG
TGGTACGACCAGA. DNA amplifications were processed by real-
time PCR (LightCycler; Roche, Basel, Switzerland). Data were
analyzed using LightCycler 3.5.28 software (Roche).
In vitro studies
Primary cultures of VSMC were obtained after enzymatic digestion
of bovine aortas and were passaged six times in flasks. For the
experiments, VSMCs were plated at 1 104 cells cm2 and incu-
bated at 36.51C in a 5% CO2 chamber. After confluence (3–4 days),
cells were incubated in DMEM containing: Ca (1.8 mM), FCS (10%),
glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino
acids, and penicillin/streptomycin. The medium was changed every
third day. Cultures were maintained at normal (7.4) or low (7.2) pH
with or without b-glycerophosphate (5 mM). At the end of the
incubation period (9 days), cells were washed with phosphate-
buffered saline and calcification was quantified: (a) by spectro-
photometry, using an OCPC Kit (Wako Diagnostics, Richmond, VA,
USA); and (b) by histology, using 1% Alizarin red stain.
Statistics
Values are expressed as the mean±s.e. The difference between
means for the two groups was determined by t-test; the difference
between means for three or more groups was assessed by ANOVA.
Po0.05 was considered significant.
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